Key facts
- It has raised $90K; the latest was Later Stage VC ($40K) in Dec 2024.
- Notable investors include University of Toronto, MaRS Investment Accelerator Fund, Viva BioInnovator, Lumira Ventures, Ontario Genomics — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Bright Angel Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Bright Angel Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Bright Angel Therapeutics
Developer of an antifungal resistance platform intended to treat life-threatening fungal infections. The company's platform helps to increase the efficacy of current treatments and eradicate drug resistance by targeting the stress responses required by fungi for survival, virulence, and drug resistance, enabling patients to overcome the frequent emergence of clinical resistance, responsible for the severe morbidity and mortality associated with infection by fungal pathogens.
- Sector
- Healthcare
- HQ
- Toronto, Canada
- Founded
- 2016
- Employees
- 4
- Website
- brightangeltherapeutics.com/
- Ownership
- Privately Held (backing)
Bright Angel Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Bright Angel Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Bright Angel Therapeutics in its N-PORT filings yet. We sweep new filings monthly.